Aciont
Envisioning the Future of Ocular Therapeutics
About Us | Unmet Needs | Technologies | Product Pipeline | Media & Investors
About Us

Ophthalmic Advisors

Paul Bernstein, M.D., Ph.D.
Dr. Bernstein is a tenured Associate Professor of Ophthalmology and Visual Sciences at the Moran Eye Center at the University of Utah School of Medicine. Paul received his M.D. and Ph.D. in Pharmacology from Harvard Medical School and graduated Summa Cum Laude. His residency was in retinal cell biology was at Jules Stein Eye Institute of UCLA School of Medicine, where he was awarded the prestigious Jules Stein Resident Research Award. Paul did his fellowship in vitreoretinal surgery and research at Massachusetts Eye & Ear Infirmary of Harvard Medical School.
Albert Vitale, M.D.
Dr. Vitale is one of the only ophthalmologists in the Intermountain West specializing in the diagnosis, medical treatment and surgical treatment of the retina, uveitis, other ocular infections and inflammatory diseases of the eye. His research interest includes ocular manifestations of systemic diseases, novel therapeutic agents, new drug delivery systems in the treatment of his specialties. He is an Associate Professor of Ophthalmology & Visual Sciences at the University of Utahís Moran Eye Center. Albert went to medical school at New York Medical College, his Residency at St. Vincentís Hospital & Medical Center in NYC and his Fellowship at Harvard University.
Nick Mamalis, M.D
Dr. Mamalis is a Professor of Ophthalmology, Director of Ophthalmic Pathology, and Director of the Intermountain Ocular Research Center at the Moran Eye Center at the University of Utah School of Medicine. Nick did his undergraduate training at Harvard University and completed Medical School and a fellowship in Ophthalmic Pathology at University of Utah. His residency was done at Loyola University Medical Center. Dr. Mamalis' research expertise is utilized by many Ophthalmic companies seeking his opinion in the areas of intraocular lenses and postoperative inflammation.

Scientific Advisors

David J. Miller, Ph.D.
David Miller has over 10 years experience with iontophoretic systems, including 5 years of research and development work on commercial iontophoretic systems. He headed interdisciplinary teams focused on transdermal iontophoretic drug delivery, and has headed an international, interdisciplinary team focused on ocular iontophoretic drug delivery. He is an inventor on several patents and has authored many papers on the related subjects. Miller received a B.S. in Pharmacy from Ferris State University, a M.S. in Pharmaceutics from the University of Michigan and a Ph.D. in Pharmaceutics from the University of Michigan.
S. Kevin Li, Ph.D.
Dr. Li is an Associate Professor at the University of Cincinnati in the Department of Pharmacy. Prior to that he was a Research Associate Professor in the Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah. He graduated Summa Cum Laude from Brigham Young University where he earned his BA in Chemistry. Dr. Li earned his Ph.D. in Pharmaceutics and Pharmaceutical Chemistry from the University of Utah. Dr. Li has published more than 25 articles ranging from permeation enhancers to alternating current iontophoresis. Dr. Li has advanced research in transdermal drug delivery, and more recently, is focusing his talents and research on transscleral drug delivery.
Sarah Molokhia, Ph.D.
Research Consultant
Sarah Molokhia has over 10 years in ocular drug delivery experience. After completing her B.S in pharmacy school, she achieved her PhD in pharmaceutical chemistry, University of Utah. Her research focus was on transscleral iontophoresis, ocular imaging and ocular pharmacokinetics. She developed a magnetic resonance imaging (MRI) method that is able to see how drugs migrate through the eye (pharmacokinetics of the drug) in real time (i.e., in vivo) after both topical and iontophoretic applications. She then joined the Moran Eye Center for a postdoctoral position for 2 years working on intraocular drug delivery implants and conjugation of biomarkers to proteins for imaging. Furthermore, she is Director of Pharmacodynamics, iVeena